Condition
Brain Metastases
ClinicalTrials.gov condition label
How to interpret these research links
Connected source recordsThis is the original ClinicalTrials.gov condition label, found in 144 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
60 shownBevacizumab Plus FSRT Versus Hippocampus-Avoidant WBRT in Lung Adenocarcinoma With Extensive Brain MetastasesNCT07481786 · 2026-03-20
RECRUITING7T Brain MRI Scan for Micro-brain Metastasis (microBM) Detection for Patients With Small-cell Lung Cancer (SCLC), Who Decline Prophylactic Cranial Irradiation (PCI)NCT07175077 · 2025-11-01
RECRUITINGPersonalized Radiotherapy for Individualized Treatment Strategies and Monitoring (PRISM)NCT07139990 · 2025-10-28
RECRUITINGA Single Arm, Phase 2 Study of Datopotamab Deruxtecan, Carboplatin, and Pembrolizumab for Treatment-naive Brain Metastases From NSCLC (Non-small Cell Lung Cancer)NCT06822543 · 2025-09-12
RECRUITINGTrastuzumab Rezetecan Combined With Radiotherapy Versus Trastuzumab Rezetecan in the Treatment of HER2-positive Advanced Breast Cancer With Brain MetastasesNCT07100600 · 2025-08-30
RECRUITINGRepotrectinib in ROS1-positive Non-small Cell Lung Cancer Patients With Active Brain MetastasisNCT06315010 · 2025-06-27
RECRUITINGBrAin Metastasis in tripLe Negateive Breast Cancer: IvoneScimab and Trop2 ADCNCT06793332 · 2024-12-17
RECRUITINGCadonilimab Combined With Stereotactic Radiotherapy as Second-line Treatment for Brain MetastasesNCT06702826 · 2024-11-01
RECRUITINGEvaluation of the Efficacy and Safety of Furmonertinib Combined with Bevacizumab As First-Line Treatment for EGFR-Positive Non-Small Cell Lung Cancer with Brain Metastases: a Single-Arm, Open-Label, Prospective Phase II Clinical StudyNCT06728865 · 2024-09-04
RECRUITINGSRT Combined With Anlotinib for the Treatment of Brain Metastases From Non-small Cell Lung CancerNCT06476093 · 2024-07-01
RECRUITINGCranial Radiotherapy Plus Chemoimmunotherapy in Untreated Driver-mutation Negative NSCLC With Stable Brain MetastasisNCT06501391 · 2024-07-01
RECRUITINGDelayed or Upfront Brain RAdiotherapy in Treatment naïve Lung Cancer Patients With Asymptomatic or Minimally Symptomatic Brain Metastases and ALK rEarrangementsNCT05987644 · 2024-03-07
RECRUITINGContribution of the CEST Sequence in the Characterization of Radionecrosis of Brain Metastases of Pulmonary OriginNCT05977803 · 2024-02-15
RECRUITINGWBRT With Hippocampal-avoidance Technique Followed by SRT for Extensive-stage SCLC With Baseline Brain MetastasesNCT06243003 · 2024-01-15
RECRUITINGBrain [18F]-FES PET/CT in Patients With Estrogen-Receptor Positive Breast CancerNCT06072807 · 2023-12-27
RECRUITINGSRS/SRT/Hypo-RT Versus HA-WBRT for No More Than 10 Brain Metastases in SCLCNCT06457906 · 2023-09-01
RECRUITINGReducing the Incidence of Symptomatic Brain Metastases With MRI SurveillanceNCT05692635 · 2023-08-30
RECRUITINGTY-9591 in the Patients With EGFR Mutations in Advanced NSCLC With Brain MetastasesNCT05948813 · 2023-08-17
RECRUITINGPhase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive MalignanciesNCT05786924 · 2023-04-18
RECRUITINGNitroglycerin Plus Radiotherapy Versus Conventional Radiotherapy in Patients With Lung Cancer.NCT06238882 · 2023-02-23
RECRUITINGUTD1 Combined With Capecitabine in Metastatic HER2-negative Breast Cancer Patients With Brain MetastasesNCT05535413 · 2023-01-01
RECRUITINGFluorine-18-AlphaVBeta6-Binding Peptide Positron Emission Tomography in Metastatic Non-Small Cell Lung CancerNCT05452005 · 2022-09-13
RECRUITINGA Study of Stereotactic Radiosurgery (SRS) for People With Lung Cancer That Has Spread to the BrainNCT05419076 · 2022-06-10
RECRUITINGThe CyberChallenge Trial How Much is Too Much - What is the Role of Cyberknife Radiosurgery in Patients With Multiple Brain Metastases?NCT05378633 · 2022-02-24
RECRUITINGSRS & Abemaciclib w/wo Imlunestrant in the Management of HR+/HER2- Breast CA Brain MetastasesNCT04923542 · 2021-11-30
RECRUITINGStereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain MetastasesNCT04899908 · 2021-09-15
RECRUITINGA Study to Evaluate the Efficacy of Osimertinib With Early Intervention SRS Treatment Compared to the Continuation of Osimertinib Alone, in Patients With EGFR Mutated NSCLC and Asymptomatic Brain MetastasesNCT05033691 · 2021-03-09
RECRUITINGStereotactic Magnetic Resonance Guided Radiation TherapyNCT04115254 · 2019-10-22
RECRUITINGPembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer PatientsNCT03449238 · 2018-11-15
RECRUITINGTrastuzumab Deruxtecan + Stereotactic Radiosurgery (SRS) in HER2+ Breast Cancer Brain MetastasesNCT07454668 · 2027-01-01
NOT_YET_RECRUITINGctDNA-Guided Intraventricular Therapy for CNS MalignanciesNCT07689721 · 2027-01-01
NOT_YET_RECRUITINGBrain Radiotherapy Combined With Dalpiciclib and Endocrine Therapy in HR-Positive/HER2-Negative Advanced Breast Cancer With Brain MetastasesNCT07539753 · 2026-06-01
NOT_YET_RECRUITINGFurmonertinib 160mg vs 80mg + Chemotherapy in EGFR-Mutated NSCLC With Brain Metastases: Efficacy and Safety StudyNCT07365410 · 2026-01-01
NOT_YET_RECRUITINGRetrospective Multicenter Study of Patient-level T1CE/FLAIR MRI Deep Learning to Predict EGFR/ALK Driver Status in NSCLC Brain Metastases With External Validation and Survival AnalysisNCT07373951 · 2025-11-01
ENROLLING_BY_INVITATIONA Two-cohort Study of SHR-A1811 in the Treatment of HER2-positive Breast Cancer With Brain MetastasesNCT07177950 · 2025-09-30
NOT_YET_RECRUITINGDual Energy CT - a Tool for Delineation of Tumor and Organs at Risk in RadiotherapyNCT07185958 · 2025-09-22
NOT_YET_RECRUITINGPhase 2 Ascending Dose Safety and Efficacy Study of RVP-001, a Manganese-based MRI Contrast AgentNCT06322342 · 2024-08-15
COMPLETEDLorlatinib in Patients With ALK-Positive NSCLC With Brain or Leptomeningeal MetastasesNCT06282874 · 2024-08-01
ACTIVE_NOT_RECRUITINGTucatinib, Trastuzumab, and Capecitabine With SRS for Brain Metastases From HER-2 Positive Breast CancerNCT05553522 · 2024-01-29
TERMINATEDANG1005 in Leptomeningeal Disease From Breast CancerNCT03613181 · 2023-12-01
UNKNOWNStudy of Cadonilimab Combined With Bevacizumab and Chemotherapy for Advanced Nonsquamous Non-small Cell Lung Cancer Patients With Untreated Brain MetastasesNCT05812534 · 2023-12-01
UNKNOWNCALM: Managing Distress in Malignant Brain CancerNCT06180460 · 2023-11-10
COMPLETEDA Phase II Study of T-DXd Plus SRT in HER2-positive Breast Cancer Brain MetastasesNCT06088056 · 2023-11-01
UNKNOWNA Retrospective Study of the Efficacy and Safety of Lolatinib in ALK+ NSCLC Patients With Brain or Meningeal MetastasisNCT06410040 · 2023-08-20
UNKNOWNSRS for NSCLC With Oligo-residual Intracranial Disease After First-line 3rd Generation EGFR-TKINCT06020066 · 2023-08-10
ACTIVE_NOT_RECRUITINGCombination Liposomal Irinotecan and Pembrolizumab For Triple-Negative Breast Cancer (TNBC) With Brain Metastases (BM)NCT05255666 · 2023-07-31
WITHDRAWNStudy to Evaluate the Safety and Efficacy of Serplulimab Plus Bevacizumab and Chemotherapy in NSCLC Patients With Brain MetastasesNCT05807893 · 2023-05-14
COMPLETEDSecondary BRain Metastases Prevention After Isolated Intracranial Progression on Trastuzumab/Pertuzumab or T-DM1 in Patients With aDvanced Human Epidermal Growth Factor Receptor 2+ brEast Cancer With the Addition of TucatinibNCT05323955 · 2023-03-23
ACTIVE_NOT_RECRUITINGSRS Timing With Immune Checkpoint Inhibition in Patients With Untreated Brain Metastases From Non-small Cell Lung CancerNCT04650490 · 2023-03-01
WITHDRAWNCirculating Tumor DNA and T Cell Repertoire Predict Radiotherapeutic Outcomes in NSCLC Patients With Brain MetastasisNCT05737589 · 2023-02-13
UNKNOWNStudy Assessing QBS72S For Treating Brain MetastasesNCT05305365 · 2022-08-16
ACTIVE_NOT_RECRUITINGTOPAZ: Tucatinib in COmbination With Pembrolizumab And TrastuZumab in Patients With HER2-Positive Breast Cancer Brain MetastasesNCT04512261 · 2022-06-01
WITHDRAWNStudy of TY-9591 in Patients With a Lung Cancer With Brain or Leptomeningeal Metastases With EGFR MutationNCT05146219 · 2022-04-02
COMPLETED(Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion MutationsNCT05241873 · 2022-03-04
TERMINATEDDose-escalation by Hypofractionated Stereotactic Radiotherapy for Brain Metastases in Non Small Cell Lung CancerNCT05588206 · 2022-01-01
UNKNOWNRadiotherapy Combined With PD-1 Inhibitors and Chemotherapy in the Treatment of NSCLC Patients With Symptomatic Brain MetastasesNCT05638425 · 2021-12-31
UNKNOWNDetection and Metabolic Characterization in DOPA PET/CT of Brain MetastasesNCT04890028 · 2021-12-03
COMPLETEDEvaluation of Neratinib for Treatment and Prevention of Subsequent CNS Event(s) in Patients With Brain Metastasis of Advanced HER2 Positive Breast CancerNCT04856475 · 2021-11-24
WITHDRAWNTKIs vs. Pertuzumab in HER2+ Breast Cancer Patients With Active Brain Metastases (HER2BRAIN)NCT04760431 · 2021-10-01
UNKNOWNTislelizumab Plus Chemotherapy as First-Line Treatment for Advanced Squamous NSCLC With Brain MetastasesNCT05207904 · 2021-06-17
UNKNOWNCommon interventions
TrastuzumabDRUG6CarboplatinDRUG5erlotinibDRUG5IcotinibDRUG5pemetrexedDRUG5Stereotactic RadiosurgeryRADIATION5PembrolizumabDRUG4OsimertinibDRUG3SRSRADIATION3Stereotactic Radiosurgery (SRS)RADIATION3WBRTRADIATION3Whole Brain RadiotherapyRADIATION3AbemaciclibDRUG2almonertinibDRUG2ANG1005DRUG2Brain RadiotherapyRADIATION2GefitinibDRUG2HA-WBRT-SIBRADIATION2ImmunotherapyDRUG2LapatinibDRUG2LorlatinibDRUG2MRIDEVICE2PertuzumabDRUG2PlaceboOTHER2Radiation TherapyRADIATION2
Leading sponsors
Sun Yat-sen University
11
Fudan University
8
Betta Pharmaceuticals Co., Ltd.
5
Angiochem Inc
3
Brigham and Women's Hospital
3
H. Lee Moffitt Cancer Center and Research Institute
3
Baptist Health South Florida
2
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
2
First People's Hospital of Hangzhou
2
Henan Cancer Hospital
2
Jules Bordet Institute
2
Li-kun Chen
2
MedSIR
2
Memorial Sloan Kettering Cancer Center
2
National Taiwan University Hospital
2
Trial status mix
UNKNOWN42
COMPLETED37
RECRUITING29
ACTIVE_NOT_RECRUITING11
TERMINATED11
WITHDRAWN7
NOT_YET_RECRUITING6
ENROLLING_BY_INVITATION1
Phase mix
PHASE287
PHASE127
NA23
PHASE312
PHASE42
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.